CITATION REPORT List of articles citing

The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer

DOI: 10.1016/j.sxmr.2015.10.004 Sexual Medicine Reviews, 2016, 4, 74-84.

Source: https://exaly.com/paper-pdf/63948634/citation-report.pdf

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
33	Rapid and sensitive liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of yonkenafil and its major metabolites in rat plasma. <i>Journal of Separation Science</i> , 2016 , 39, 3700-3708	3.4	1
32	In vitro and in vivo investigation of natural compounds from seed extract of Mucuna pruriens lacking l-DOPA for the treatment of erectile dysfunction. <i>Asian Pacific Journal of Tropical Medicine</i> , 2017 , 10, 238-252	2.1	10
31	The Graham Jackson Memorial Lecture ISSM 2016-"The Man Who Knew Too Much": Time to Recognize Erectile Dysfunction and Low Testosterone as Independent Risk Factors for Cardiovascular Disease. <i>Sexual Medicine Reviews</i> , 2017 , 5, 256-265	5.6	11
30	NO-Sensitive Guanylate Cyclase Isoforms NO-GC1 and NO-GC2 Contribute to Noise-Induced Inner Hair Cell Synaptopathy. <i>Molecular Pharmacology</i> , 2017 , 92, 375-388	4.3	18
29	PDE5 Overexpression in Well-Differentiated Thyroid Carcinomas Is Associated with Lymph Node Metastasis. <i>International Journal of Endocrinology</i> , 2017 , 2017, 6243932	2.7	O
28	Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction. <i>Sexual Medicine Reviews</i> , 2018 , 6, 242-252	5.6	53
27	Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents. Ecancermedicalscience, 2018 , 12, 824	2.7	24
26	Repurposing mechanistic insight of PDE-5 inhibitor in cancer chemoprevention through mitochondrial-oxidative stress intervention and blockade of DuCLOX signalling. <i>BMC Cancer</i> , 2019 , 19, 996	4.8	10
25	Targeting cyclic nucleotide phosphodiesterase 5 (PDE5) in brain: Toward the development of a PET radioligand labeled with fluorine-18. <i>Bioorganic Chemistry</i> , 2019 , 86, 346-362	5.1	8
24	Soluble guanylate cyclase isoenzymes: The expression of 🗓, 🗓, and 🖟 subunits in the benign and malignant breast tumors. <i>Journal of Cellular Physiology</i> , 2020 , 235, 1358-1365	7	4
23	Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy. <i>Cancers</i> , 2020 , 12,	6.6	14
22	Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer. <i>Nature Communications</i> , 2020 , 11, 3191	17.4	10
21	Reverting Immune Suppression to Enhance Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2019 , 9, 1554	5.3	22
20	Current Status and Prospects in the Treatment of Erectile Dysfunction by Adipose-Derived Stem Cells in the Diabetic Animal Model. <i>Sexual Medicine Reviews</i> , 2020 , 8, 486-491	5.6	5
19	Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics. <i>Seminars in Cancer Biology</i> , 2021 , 68, 258-278	12.7	40
18	Repurposing of Phosphodiesterase-5 Inhibitors as Therapeutic Agents Against Human Gastric Cancer. SSRN Electronic Journal,	1	
17	Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics. <i>Vaccines</i> , 2021 , 9,	5.3	19

CITATION REPORT

16	New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs. <i>Cells</i> , 2021 , 10,	7.9	5
15	Overexpression of GUCY1A2 Correlates With Poor Prognosis in Gastric Cancer Patients. <i>Frontiers in Oncology</i> , 2021 , 11, 632172	5.3	2
14	8-Alkylmercaptocaffeine derivatives: antioxidant, molecular docking, and in-vitro cytotoxicity studies. <i>Bioorganic Chemistry</i> , 2021 , 111, 104900	5.1	2
13	Phosphodiesterase type 5 inhibitors use and risk of colorectal cancer: a systematic review and meta-analysis. <i>International Journal of Colorectal Disease</i> , 2021 , 36, 2577-2584	3	1
12	Beyond immunosuppressive effects: dual roles of myeloid-derived suppressor cells in bone-related diseases. <i>Cellular and Molecular Life Sciences</i> , 2021 , 78, 7161-7183	10.3	1
11	NO-HDAC dual inhibitors. European Journal of Medicinal Chemistry, 2022, 227, 113934	6.8	1
10	Hydroalcoholic Extract of Levisticum officinale Increases cGMP Signaling Pathway by Down-Regulating PDE5 Expression and Induction of Apoptosis in MCF-7 and MDA-MB-468 Breast Cancer Cell Lines. <i>Iranian Biomedical Journal</i> , 2019 , 23, 280-6	2	2
9	How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme <i>Pharmacological Reports</i> , 2022 , 1	3.9	O
8	Pros and Cons of Pharmacological Manipulation of cGMP-PDEs in the Prevention and Treatment of Breast Cancer <i>International Journal of Molecular Sciences</i> , 2021 , 23,	6.3	1
7	Table_1.pdf. 2020 ,		
6	Use of Phosphodiesterase-5 Inhibitors and the Risk of Melanoma. SSRN Electronic Journal,	1	0
5	Novel Chemicals Derived from Tadalafil Exhibit PRMT5 Inhibition and Promising Activities against Breast Cancer <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
4	Integration of Transcriptomics and Metabolomics Reveals the Antitumor Mechanism Underlying Tadalafil in Colorectal Cancer. <i>Frontiers in Pharmacology</i> , 2022 , 13,	5.6	
3	Fadogia agrestis (Schweinf. Ex Hiern) Stem Extract Restores Selected Biomolecules of Erectile Dysfunction in the Testicular and Penile Tissues of Paroxetine-Treated Wistar Rats.		
2	Novel 9-Benzylaminoacridine Derivatives as Dual Inhibitors of Phosphodiesterase 5 and Topoisomerase II for the Treatment of Colon Cancer. 2023 , 28, 840		0
1	Intracellular cGMP increase is not involved in thyroid cancer cell death. 2023 , 18, e0283888		Ο